Individualizing Treatment in the Management of Advanced Breast Cancer: How Novel Therapies Are Changing the Treatment Paradigm

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2019 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from July 1, 2019 to July 1, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
AstraZeneca LP and Merck & Dohme Corp.

Description:
Breast Cancer is the most common cancer found in women, regardless of race or ethnicity. The incidence in women in the United States is 1 in 8 (about 12 percent). Death rates have been steadily decreasing over the past 20 years due to new and ever improving treatment options, however therapy in the metastatic setting focuses on prolonging life and managing disease-and treatment-related adverse events. There is no single treatment strategy that will work for all patients with metastatic breast cancer (MBC). Instead, treatment selection must be individualized based upon patient- and tumor-specific factors, as well as safety and efficacy profile of available agents, with an emphasis on the combined goals of tumor control, prolonged survival, and maintenance of patient quality of life. Fortunately for patients with advanced breast cancer, several new agents have recently become available. They have shown the ability to improve safety and efficacy outcomes, especially in the area of HER2- metastatic breast cancer. Nearly 80% of patients with advanced breast cancer have the HER2-negative subtype and therefore are not candidates for HER2-targeting therapies. Thankfully, therapy for advanced breast cancer is increasingly personalized due to an array of molecularly targeted/endocrine therapies indicated for recurrent/advanced disease. New classes of targeted agents, including PARP inhibitors, have been recently introduced and are changing the treatment paradigm.

Upon completion of this activity, participants will be able to:

  • Examine patient-centric navigation through the complex pathways required in the increasingly personalized care of advanced breast cancer

  • Analyze the main signaling pathways and key mechanisms in DNA damage repair and how deficiencies in these pathways can lead to tumor proliferation and growth

  • Compare and contrast efficacy and safety profiles of new and emerging targeted therapies, including PARP inhibitors, for the treatment of advanced breast cancer

  • Explore key evidence from PARP inhibition trials in breast cancer, and report recent findings from investigations evaluating potential new roles for these approaches

  • Assess evolving data regarding the adverse event profiles of PARP inhibitors currently approved and in clinical development for patients with breast cancers

  • Analyze methods to enable optimal cost management of PARP inhibitors to be realized by multiple breast cancer stakeholders including managed care organizations
     

Faculty: Hatem Soliman, MD
Breast Medical Oncology
Chair Clinical Research Advisory Committee
H. Lee Moffitt Cancer Center and Research Institute
Associate Professor, Division of Oncologic Sciences
University of South Florida

Disclosure:

Dr. Soliman serves as a consultant for AstraZeneca, Celgene, Eisai, Eli Lilly, Pfizer. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by educational grants from
AstraZeneca LP and Merck & Dohme Corp.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue